VC, IT, deals Wade Roush wrote: Burlington, MA-based Veracode, which tests corporate software for back doors and other security holes by analyzing its raw binary code, has  collected half of a $10 million third financing round, according to a regulatory filing cited by PE Hub. The investors for the...

Roundup, deals, VC Rebecca Zacks wrote: It was a mixed week for New England’s tech and life sciences firms, with several sizeable venture deals closed and a few less happy transactions as well. —Ariad Pharmaceuticals (NASDAQ:ARIA) cut a $24.3 million deal with new and existing institutio...

Roundup, Life Sciences, strategy Rebecca Zacks wrote: If you’re a fan or follower of New England’s life sciences industry we’ve got lots for you this week, thanks to some great in-depth reporting by Ryan and Luke. —Luke gave a fascinating look at the strategy of Cambridge, MA...

VC, Life Sciences, Immune Diseases Ryan McBride wrote: Selecta Biosciences, a secretive biotech startup, is breaking its silence today to reveal the closing of a $15.1 million second round of financing. The sizable round is a rarity during what has been a financial drought for most young biotech fir...

VC, deals, stock Wade Roush wrote: Sim Simeonov, a general partner at Waltham, MA-based Polaris Venture Partners, is conducting an online survey to find out how much stock dilution technology startup founders generally experience between the creation of their companies and the all-important exit eve...

Roundup, deals, VC Rebecca Zacks wrote: We’ve got several different venture deals to talk about this week, as well as an acquisition, a sizeable secondary offering, and other interesting transactions from New England’s tech and life sciences firms. —Cardiac implant maker HeartWare ...

Life Sciences, VC, vaccines Ryan McBride wrote: Genocea Biosciences, a Cambridge, MA-based startup built around rapid vaccine discovery technology licensed from Harvard Medical School, says it has raised $23 million in a Series A round of financing and named biotech industry veteran Staph Leavenwort...

Life Sciences, Antibodies, cancer Ryan McBride wrote: Adimab is taking an uncommon approach to exploiting the value of its antibody-discovery technology. The Lebanon, NH-based biotech startup has no plans to ever develop its own drugs—CEO Tillman Gerngross says he thinks Adimab can become succ...

IT, energy, Life Sciences Ryan McBride wrote: It takes about two hours to drive to Dartmouth College from the Boston area—not nearly as convenient as the 15- or 20-minute trip that many of the area’s venture capitalists can make between their firms and Harvard or MIT. Nevertheless, some ...

Roundup, deals, VC Rebecca Zacks wrote: Once again, New England’s tech and life sciences firms have managed to eek out a few notable deals despite the daunting climate. —Idenix Pharmaceuticals (NASDAQ: IDIX), a maker of infectious-disease treatments in Cambridge, MA, forged an alliance w...